This article has been updated to include a statement from UpScriptHealth. In August 2024, Pfizer Inc (NYSE:PFE) introduced ...

JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy ...

tofacitinib (Xeljanz, Pfizer) 5 mg twice per day and upadacitinib (Rinvoq, Abbvie) 15 mg daily. The meta-analysis ultimately included nine randomized controlled trials representing a total of ...

Despite a drop in legacy product sales like Xeljanz, Pfizer demonstrated resilience through effective cost management. Notably, Pfizer's R&D expenditure rose by 8% operationally, reinforcing its ...

Higher-priced drugs, including Vyndaqel, Ibrance, Xtandi and Xeljanz, are expected to be most affected by the IRA. Pfizer expects Comirnaty and Paxlovid to maintain market share in 2025 with ...

Pfizer (PFE) reported $17.76 billion in revenue ... Revenues- Specialty Care- Xeljanz- Worldwide: $349 million compared to the $323.32 million average estimate based on three analysts.

Pfizer reported fourth-quarter 2024 adjusted ... However, sales of some key drugs like Prevnar, Xeljanz and Ibrance and new RSV vaccine, Abrysvo declined in the quarter. Seagen drugs contributed ...